We show that ruxolitinib-mediated suppression of the STAT3/5-AKT pathway in the CD8+ T cells in SLE-PBMCs in the presence or absence of UCB-Tregs might suggest an independent mechanism of targeting SLE pathogenesis, since inhibition of STAT3 in T cells in lupus has been shown to delay the onset of nephritis (34). This evidence concerns the gene AKT1 and systemic lupus erythematosus.